

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心璋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**VOLUNTARY ANNOUNCEMENT
EMBOLIC COIL RECEIVED NMPA APPROVAL**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The Company is pleased to announce that the Company has recently received the approval from the National Medical Products Administration of the PRC (國家藥品監督管理局) (“**NMPA**”) for the registration application for the Embolic Coil, making it the Company’s eleventh NMPA approved neuro-interventional product.

As of the date of this announcement, the Company has obtained NMPA approved products in each of the four aspects of the neuro-interventional treatment device market, including ischemic stroke thrombectomy devices, intracranial stenosis treatment devices, hemorrhagic stroke treatment devices, and vascular access devices.

There is no assurance that the Embolic Coil will ultimately be successfully marketed and/or commercialized by the Company. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Wang Guohui
Chairman of the Board

Shanghai, March 17, 2022

As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.